The migration of cancer cells towards gradients of chemoattractive factors represents a potential, yet elusive, mechanism that may contribute to cancer cell dissemination. Here we provide evidence for the maintenance of a gradient of increasing CCL8 concentration between the epithelium, the stroma and the periphery that is instrumental for breast cancer cells' dissemination. In response to signals elicited by the neoplastic epithelium, CCL8 production is enhanced in stromal fibroblasts at the tumor margins and in tissues at which breast cancer cells tend to metastasize such as the lungs and the brain. Manipulation of CCL8 activity influences the histology of the tumors and promotes major steps of the metastatic process such as invasion to adjacent stroma, intravasation and ultimately extravasation and seeding. These findings exemplify how gradients of chemoattractive factors such as CCL8, drive metastasis and suggest that interference with their operation may provide means for breast cancer management.
INTRODUCTION
Tumor cell dissemination reflects the collective outcome of multiple events that include the invasion of cancer cells into the surrounding stroma, subsequently their intravasation and entrance into the circulation, and ultimately their extravasation and seeding into sites of secondary growth. 1, 2 The role of the stroma in these processes is being increasingly appreciated as it establishes positive feedback loops with the neoplastic component of tumors inducing epithelialmesenchymal transition (EMT) and promoting invasion. [3] [4] [5] [6] [7] In turn, EMT provides a stochastic mechanism by which cancer cells, by acquiring enhanced motility, increase their likelihood to invade adjacent tissues. 8 In addition to random cell migration, directed cell migration towards specific gradients of chemokines, cytokines and growth factors may also contribute to the spread of cancer cells and the initiation of the metastatic process as recognized 415 years ago following the description of the CXCL12/CXCR4 paradigm and its role in breast cancer metastasis. 9 However, the contribution of the epithelium in the maintenance of such gradients remains inadequately understood. We hypothesized that soluble factors produced by the stroma in response to signals elicited by the epithelium may facilitate the establishment and maintenance of gradients that could trigger the directional migration of the cancer cells promoting their dissemination. It is conceivable that these gradients may operate both within the tumor microenvironment driving the invasion of cancer cells into the surrounding stroma, and towards the systemic circulation promoting intravasation and establishment of populations of circulating tumor cells (CTCs). Ultimately, local production of chemoattractive factors in distal tissues may promote seeding of CTCs and establishment of metastatic foci.
To explore these hypotheses, we used breast cancer cells as a model and focused on a conserved chemokine cluster located in chromosomes 11C in mice and 17q12 in humans. This cluster harbors several chemoattractive cytokines many of which previously have been associated with tumorigenesis, primarily through generation of a tumor-promoting pro-inflammatory microenvironment (Figure 1a [10] [11] [12] ).
RESULTS

Cancer cells activate CCL8 expression in fibroblasts by paracrine mechanisms
To test if stromal fibroblasts are responsive to epithelium-derived signals, we exposed mouse 3T3 and human HFFF2 fibroblasts to conditioned media from the metastatic human triple negative breast cancer (TNBC) cells MDA-MB-(MDA)231 and MDA-MB-(MDA) 468 and monitored the expression of chemokines CCL1, CCL2 (MCP-1, monocyte chemoattractant protein 1), CCL7 (MCP-3), CCL8 (MCP-2) and CCL11 in both mouse and human cells, as well as CCL13 in human and Ccl12 in mouse cells. CCL13 is a humanspecific cytokine while Ccl12 is a mouse-specific cytokine. As shown in Figure 1b CCL7 was induced only in human fibroblasts and Ccl11 only in mouse fibroblasts, with CCL8 being stimulated in both mouse and human cells. Thus, we focused on CCL8, a chemoattractive cytokine that signals through multiple receptors including CCR1, CCR2B, CCR5 and CCR8 [13] [14] [15] in mouse and/or human cells. CCL8 emerges as a good candidate for promoting oncogenesis for several additional reasons: It has been shown that breast cancer cells can activate CCL8 production in adjacent stromal fibroblasts. 16 CCL8 has also been identified by proteomic analyses as a stroma-derived protein in experimental colon cancers, 17 while its levels were significantly elevated in the plasma of breast cancer-prone mice during disease progression. 18 In addition, in a recent study, CCL8 expression has been shown in the melanoma microenvironment. 19 The importance of CCL8 in mammary tumorigenesis is also supported by breast tumor expression data (Oncomine, https://www.oncomine.org), showing elevated expression of this cytokine in the stroma of breast tumors as compared with controls ( Figure 1c 20 ). Furthermore, high-CCL8 expression in tumors (Kaplan-Meier Plotter (Breast Cancer) www. kmplot.com/, 21 Cancer Genomics Browser, the University of California at Santa Cruz, https://genome-cancer.ucsc.edu/) is associated with worse prognosis in breast cancer patients (Figure 1d , Supplementary Figure S1 ). Noteworthy, this prooncogenic role of CCL8 appears to be specific for breast and also cervical cancers because in tumors of other anatomical sites, such as those of colon, pancreas, lungs and others, did not show association with disease outcome (Supplementary Figure S1 ).
The ability of breast cancer cells to stimulate CCL8 in fibroblasts was not retained for all breast cancer cells: When fibroblasts were exposed to media from a panel of breast cancer cells only those from TNBCs MDA231 and MDA468 cells were stimulatory while media from the estrogen-dependent MCF7, BT474 and T47D were not, for either CCL8 (Figure 1e ) or CCL7 (data not shown). An intriguing possibility is that in breast cancer cells estrogenindependency is linked to the production of soluble factors that can stimulate CCL8 expression in adjacent fibroblasts, 'educating' Figure 1 . Establishment of a self-sustained CCL8 gradient between breast cancer and stromal cells. (a) Genomic organization of the cytokine cluster that harbors Ccl8 in mouse and humans. Data were compiled from Ensembl Genome Browser (www.ensembl.org). (b) Cytokine expression in human HFFF2 and mouse 3T3 fibroblasts following culture in MDA231 and MDA468 breast cancer cell conditioned media. Ccl8 is the only cytokine in this cluster that specifically responds to breast cancer cells' media in both mouse and human fibroblasts. (c) Expression of CCL8 in human invasive breast cancer stroma. Data were obtained by Oncomine, https://www.oncomine.org. (d) Breast cancer patients' survival in relation to CCL8 expression. High-CCL8 expression is associated with worse prognosis. Data were obtained from Kaplan-Meier Plotter (Breast Cancer), www.kmplot.com/. High expression is indicated in red, low expression in blue, cutoffs were set automatically by the software. (e) Ccl8 expression in mouse and human fibroblasts following exposure to breast cancer cells' conditioned media. *Po0.01, Student's t-test. stroma in a pro-oncogenic manner. Consistently with this notion, the ability of TNBCs and estrogen-positive cancers to 'educate' differentially stromal cells has been demonstrated. 11, 22, 23 The profile of CCL8-inducibility was overlapping in human and mouse cells implying the conservation of the breast cancer cell-derived factors between humans and mice since human cell-derived factors could operate effectively onto mouse cells eliciting responses of similar pattern and magnitude ( Figure 1e ). Mouse breast cancer cells (4T1 and EO771) were incapable of stimulating CCL8 expression in either 3T3 or HFFF2 fibroblasts under these conditions while prolonged conditioning of media, for 4 days, was stimulatory (data not shown). Of those two mouse breast cancer lines used, EO771 is estrogen receptor positive, 24 which is in line with the inability of human cells to stimulate CCL8 in fibroblasts. However, 4T1 is considered a model of triple negative breast cancer, 25 which contrasts the behavior of human breast cancer cells, a discrepancy that implies intrinsic differences in the biology of human and mouse breast cancers.
CCL8 attracts breast cancer cells in vitro
Given the strong chemoattractive activity of CCL8 for immune cells, 26, 27 we asked if this chemokine is able to attract breast cancer cells. As shown in Figure 2a , both mouse and human CCL8 attracted breast cancer cells of either mouse or human origin, but not fibroblasts. Furthermore, human and mouse CCL8 are functionally interchangeable because they could reciprocally attract mouse and human cells. This ability of CCL8 to induce the migration of breast cancer cells was also associated with induction in the levels of the mesenchymal marker vimentin which underlines an increase in cellular motility (Supplementary Figure S2 ). This effect, however, is not likely associated with the prototypical activation of EMT since slug and snail induction was virtually absent. Considering that CCL8 and other chemokines act primarily on leukocytes that may migrate by amoeboid movements, 28 similar effects on breast cancer cells are conceivable. In addition, selection of specific cell populations rather than modification of the cells' transcriptional program remains also as a possibility. To rule out though the possibility that the elevation in cell migration by CCL8 was due to an overall increase in cell motility and not associated with chemoattraction, we compared the migration of MDA231 cells in transwells at which CCL8 was placed in the lower chamber versus distributing it evenly between the lower and upper chambers. As shown in Figure 2b , cells migrated from lower towards increased CCL8 concentration while migration was not stimulated when equal amounts of CCL8 were maintained between transwells. In addition, human CCL20 had only a minor effect in the migration of MDA231 cells, as it has been previously shown 29 (Supplementary Figure S3 ).
To identify the specific receptors that mediate MDA231 cells' migration towards human CCL8, we hypothesized that the particular MDA231 cells expressing these receptors at higher levels will be enriched in the lower chamber of a transwell following CCL8induced chemoattraction. Following normalization versus untreated cells in transwells and cells treated with CCL8 in a regular well (no migration and thus no enrichment), we were able to record enrichment of CCR1 and CCR3 ( Figure 2c ).
The fact that both the stimulus for CCL8 production and the target for CCL8-induced chemoattraction are the cancer cells predicts the establishment of a paracrine loop of repeated cycles of 'stromal CCL8 activation-cancer cell attraction'. This loop, involves both stromal and cancer cells establishing a self-sustained gradient of CCL8 around the fibroblasts that will progressively stimulate cancer cells' movement ( Figure 2d ).
Expression profile of Ccl8 in tumors, stroma and peripheral tissues By using EO771 mouse breast cancer isografts as a model, we sought to explore further this hypothesis and the implications of CCL8-based gradients in tumorigenesis. EO771 cells have originally been derived from breast tumors in C57BL6 mice, 30 which permit their inoculation in syngeneic Ccl8-deficient animals. 31 Despite their limited ability to stimulate Ccl8 expression in fibroblasts, we reasoned that EO771 isografts represent adequate system to study the role of a Ccl8 gradient between the stroma and the epithelium because EO771 cells express lower levels of Ccl8 than stromal cells in vivo as indicated by the fact that EO771 tumors growing in wild-type (wt) mice had significantly higher Ccl8 levels than tumors growing in Ccl8KO mice (Figure 3a ). Thus, increasing levels of Ccl8 can be maintained between the epithelium and the stroma despite that it is not the cancer cells that actively induce and maintain fibroblasts' Ccl8 production. Consistently with the stromal origin of Ccl8, anti-CCL8 immunoreactivity was detected in stromal cells of EO771 tumors, especially at the tumor margins ( Figure 3b , Supplementary Figure S4 ). Noteworthy, a correlation between the levels of circulating Ccl8 in tumor-bearing wt mice and EO771 tumor size was detected (Figure 3c , Supplementary Figure S5 ), which in association with the inability of EO771 cells to activate Ccl8 expression in 3T3 and HFFF2 fibroblasts was unexpected. In addition, RAW 264.7 macrophages and MEFs did not exhibit elevated levels of Ccl8 when cultured in EO771conditioned media rendering unlikely that the increased levels of plasma Ccl8 in tumor-bearing mice are due to stimulation of Ccl8 expression in stromal cells (data not shown). In view of the fact that cells of the microenvironment constitute the major source of Ccl8, it is plausible that larger tumors mobilize higher numbers of Ccl8-producing stromal cells than smaller tumors, thus elevating total circulating Ccl8 levels. Indeed, besides the stromal fibroblasts that are abundant in the periphery of EO771 tumors, macrophages that also express Ccl8 are over-represented in tumor margins (Supplementary Figure S6 ). In addition, peripheral tissues may also activate Ccl8 production in response to tumor-derived signals, contributing to the increased levels of circulating Ccl8 in the tumorbearing mice. Measurement of Ccl8 amounts in various organs showed elevated levels of this cytokine in peripheral tissues of tumor-bearing as compared with tumor-free animals ( Figure 3d ). These tissues included the lungs and the brain that represent common sites of metastatic growth for breast cancers (Figure 3d ). In mammary glands the highest amounts of Ccl8 were detected, which despite the fact that their levels were not elevated in the breast tumor-bearing mice they still remained higher than those of the Ccl8 levels in the tumors (Figure 3d ). This likely re-enforces the maintenance of the Ccl8 gradient towards the periphery of the tumors and probably contributes to the unique association between breast cancer prognosis and Ccl8 expression.
Consequences of Ccl8 inhibition in the profile of tumorigenesis and histopathology of tumors
Then we asked the consequences of Ccl8 inhibition in tumor onset. First we blocked Ccl8 activity by a neutralizing antibody administered daily for 5 days in wt C57B6 mice following orthotopic inoculation of the syngeneic EO771 mammary breast cancer cells. As shown in Figures 4a and b, inhibition of Ccl8 activity only moderately delayed the onset of EO771 breast tumors. Then we tested the effects of genetic ablation of Ccl8 in the onset of EO771 breast tumors. Consistently with the effects of antibody-mediated inhibition, genetic deletion of Ccl8 also modestly delayed the onset of EO771 tumors (Figure 4c ). Despite the limited effects in the kinetics of implanted breast tumors, Ccl8 deficiency in the stroma resulted in tumors with increased cellularity, better-defined borders ( Figure 4d ) and less stroma as indicated by Van Gieson staining for elastic fibers (Figure 4e ). Furthermore, vimentin expression close to tumor margins was more intense in the tumors developed in wt than Ccl8KO mice (Figure 4f ). Thus, stroma-derived Ccl8 confers characteristics that are associated with the increased ability of cancer cells to disseminate.
CCL8 mediates invasion of breast cancer cells towards adjacent fibroblasts in vivo
The histopathology of the tumors with stromal Ccl8 ablation, the chemoattractive activity of Ccl8 onto breast cancer cells and the maintenance of a Ccl8 gradient between the stroma and the epithelium are in line with a stimulatory role for this cytokine in the metastatic potential of the cancer cells. Attempts to detect CTCs in the blood or metastatic foci in the lungs of EO771 tumorbearing wt or Ccl8KO mice resulted only in their marginal detection in the wt animals, at levels though below those permitting comparison between experimental groups. Thus we utilized the highly metastatic MDA231 human breast cancer cell line and manipulated either directly or indirectly CCL8 levels in tumor-bearing animals to reveal evidence of differential metastatic potential. As described above, MDA231 cells are highly sensitive to CCL8-induced chemoattraction and efficiently stimulate fibroblasts' CCL8 production by a paracrine manner. In addition, when MDA231 cells were implanted orthotopically in nude mice, Ccl8 levels were stimulated in peripheral tissues in a manner exhibiting the same pattern with that recorded when EO771 cells were implanted in C57BL6 wt mice (Figure 5a versus Figure 3d ). In addition, mouse Ccl8 levels in the serum increase in association with tumor size, further confirming the ability of MDA231 cells to activate the production of Ccl8 in the host (Supplementary Figure S7) . Thus, they constitute an adequate system to study the role of stroma-derived Ccl8 in breast cancer.
Initially we sought to explore if fibroblast-derived CCL8 can drive invasion of cancer cells to adjacent stroma. To attain this, CCL8 expression should be stimulated in stromal fibroblasts in the vicinity of the tumors and then it should be able to attract the cancer cells triggering their dissemination. To test this, HFFF2 fibroblasts were enclosed in matrigel and inoculated s.c. in mice close to MDA231 tumors or in tumor-free mice (Figure 5b ). As shown in Figure 5c , in line with the conditioned media-based experiments described in Figure 1 , HFFF2 fibroblasts close to cancer cells exhibited elevated expression of CCL8 as compared with fibroblasts that had been inoculated in tumor-free mice. Then, we recorded the invasion of MDA231 cells towards the HFFF2 matrigel nodules and found that it was stimulated by a manner that is CCL8-dependent since treatment of mice with a neutralizing antibody for CCL8 blocked their invasion (Figures 4d-f ). Thus in vivo, CCL8 that is triggered in fibroblasts in response to signals elicited by breast cancer cells guides their invasion to adjacent stroma.
CCL8 induces extravasation of breast cancer cells
The chemoattractive activity of CCL8 predicts that elevated levels of CCL8 in the blood may also stimulate intravasation of the cancer cells. 32, 33 The existence of CTCs is a pre-requisite of hematogenous metastasis and their number represents a good reflection of the pro-metastatic activity of tumors. 34, 35 To that end, we measured the number of CTCs in mice bearing MDA231 tumors following i.v. administration of hCCL8. After 24 h, CTCs were evaluated by quantitative PCR for human cytokeratin 19 by using total RNA from PBMCs as template, the amount of which had been normalized for mGAPDH. As shown in Figure 5g , hCCL8 effectively stimulated the extravasation of MDA231 cells and increased their abundance in the blood, which is in line with a pro-metastatic role for this cytokine.
CCL8 promotes seeding of breast cancer cells in the periphery
Since CCL8 operates as a chemoattractant it is conceivable that tissues with elevated levels of CCL8 would attract more efficiently breast cancer cells facilitating their seeding and the development of sites of secondary growth. Therefore, MDA231-β-Gal cells were injected i.v. in nude mice and the efficiency of seeding in the mammary glands that express high Ccl8 levels was evaluated (Figure 5h ). As shown in Figure 5i , MDA231-β-Gal cells colonized the mammary glands by a manner that was CCL8-dependent because anti-CCL8 treatment after cancer cell injection nullified the number of the resulting MDA231 foci in the mammary fat pad (Figure 5j, Supplementary Figure S8) . A similar trend, albeit insignificant, was also detected in the colonization of the lungs (Supplementary Figure S9) . Thus, CCL8 does not only promote intravasation in the primary sites of tumor growth but also extravasation and establishment of secondary growth by enhancing cancer cell seeding.
DISCUSSION
Collectively these findings are consistent with the establishment of a gradient of CCL8 that facilitates the communication between the neoplastic epithelium and the stroma and promotes the motility and directional migration of cancer cells. This CCL8-based gradient is self-sustained because it can be maintained by the constitutive production of the cytokine by the stroma that is more abundant in the tumor margins and is potentiated by signals elicited by the epithelium. The breast tumor-associated stimulation of CCL8 levels in the lungs and the brain implies that their seeding by circulating breast cancer cells during tumor growth is not merely due to the increased possibilities of larger tumors to metastasize but is a rather dynamic feature sustained by paracrine signals originating from the neoplastic epithelium. Depending on its relative levels in the blood, the tumors and the peripheral tissues, CCL8-like gradients can further mobilize cancer cells by promoting intravasation at the primary site or by triggering extravasation and metastatic seeding at distal locations. The abundance of CCL8 in the normal mammary tissue may contribute to tumor self-seeding that has been described before for breast and other cancers. 36 In this case though it appears that tumor self-seeding is promoted by a stroma-derived factor rather than cancer cell-derived factors. 36 A potential implication of this hypothesis is that field cancerization may not reflect only de novo malignant conversion of the epithelium 37 but also the onset of secondary tumors from cells that have disseminated from the primary tumor and established local outgrowths in the vicinity of the primary tumors or they are due to metastatic foci from cancer cells that had been attracted from the circulation.
In view of the fact that both the genetic and the antibodymediated inhibition of CCL8 activity interfered with the motility of cancer cells and their invasive/metastatic activities suggest that anti-CCL8 therapy should be considered for the management of metastatic breast cancer. Such approach is not expected to produce considerable adverse effects, as suggested by the absence of visible phenotypes in the CCL8KO mice and the welltolerated administration of neutralizing antibodies. It is noted that recently the neutralization of CCL2 has been explored for prostate cancer. 38, 39 Although the exact contribution of CCL8 in human breast cancers remains to be determined, these findings exemplify how CCL8-like gradients can drive the metastatic process by promoting invasion, intravasation and ultimately extravasation and seeding into sites of secondary growth ( Figure 6 ).
MATERIALS AND METHODS
Cell culture MDA-MB-231, MDA-MB-468, MCF7, 3T3, 4T1, RAW 264.7 and HFFF2 cell lines were cultured in DMEM with 10% HyClone FetalClone II serum (Thermo Scientific, Waltham, MA, USA). BT474, T47D and EO771 cells were cultured in RPMI 1640 medium supplemented with 10% FBS HyClone FetalClone II serum. The C57BL/6-derived breast cancer cell line EO771 was obtained from Dr Frank C. Marini (Wake Forest School of Medicine, Winston-Salem, NC, USA). EO771 cells prior to mice inoculation were tested for viral pathogens and mycoplasma contamination (IDEXX Bioresearch, Columbia, MO, USA). HFFF2 cells were obtained as cryopreserved cells from Sigma-Aldrich (St Louis, MO, USA) and were used in all assays between passage 5 and 10. All other cell lines were originally obtained from ATCC (Manassas, VA, USA) and subsequently maintained in our laboratory. Most recent authentication was performed 1 month prior to submission by STR analysis (Biosynthesis, Lewisville, TX, USA). MDA231 cells were transfected with pcDNA3.1-β-Galactosidase-expressing plasmid, using TurboFect Transfection Reagent (Thermo Scientific) according to the manufacturer's instructions followed by selection with 1 mg/ml G418. All cell lines were frequently tested for mycoplasma contamination using commercially available Mycoplasma detection kit (Myco Alert kit, Lonza, Walkersville, MD, USA).
Conditioned media
For conditioning of media, cells were plated in duplicates on six-well plates at a starting density of 4 × 10 5 cells per well for 48 h. Conditioned media were collected and centrifuged for 5 min at 1200 r.p.m. to remove cell debris. Then, 3 ml of the conditioned media was added for 48 h in HFFF2 or 3T3 fibroblasts that had been cultured for 16 h in serum-free media on six-well plates at a density of 2.5 × 10 5 cells per well. Experiments were performed at least thrice each time in duplicates, and similar results were obtained.
Migration assays
About 10 4 cells were seeded on the top chamber of the transwells (24-well format, with 8-μm pore size insert, Costar, Waltham, MA, USA) in serumfree media and inserted in the plates containing 600 μl of medium supplemented with 10% FBS and the desired concentration of chemoattractant (human or mouse recombinant CCL8, Cellgs, human CCL20, Biolegends, San Diego, CA, USA) into the lower chamber. After 16 h, the upper sides of transwells were washed in PBS, scraped gently with a cotton swab to remove cells that did not migrate and then cells on the lower side of membrane were fixed with methanol and stained with hematoxylin. Migrated cells were counted under microscope and counts were performed by two independent observers blinded to treatment. For receptors expression, RNA was isolated from migrated cells treated with human CCL8 for 5 h and also cells that were treated in regular wells under the same conditions. Experiments were performed at least thrice, each time in duplicates and representative results are shown.
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Stromal cells (fibroblasts, monocytes)
Vessel Center Periphery Figure 6 . Diagrammatic illustration of how a gradient of CCL8 is self-sustained to promote dissemination of breast cancer cells. Fibroblasts and probably other stromal cells are activated in response to secreted factors produced by the breast cancer cells (a) and activate CCL8 expression which results in the establishment of a CCL8 gradient (b). This results in the chemoattraction of the cancer cells towards the CCL8 gradient causing progressively their movement along with the shift of the gradient towards the tumor margins at which stromal cells are more abundant (c). Eventually cancer cells intravasate in response to elevated levels of CCL8 in circulation establishing CTC populations (d). Ultimately, niches of increased CCL8 production in peripheral tissues promote the extravasation of cancer cells and the establishment of populations of secondary tumor growth (e).
RNA and protein assays
Total RNA was extracted from cultured cells using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. PrimeScript RT reagent kit-Perfect Real Time (Takara Bio, Shiga, Japan) for reverse transcription-PCR was used for complementary DNA (cDNA) synthesis according to the manufacturer's protocol. Total RNA was extracted from cultured cells and tissues using RNeasy Mini Kit according to the manufacturer's protocol. For CTCs detection, peripheral blood samples from mice were obtained from retro-orbital venous plexus sampling in tubes containing EDTA. Red blood cells were lysed using red blood cells lysis buffer and RNA was extracted from PBMCs using RNeasy Micro Kit (Qiagen) according to the manufacturer's protocol. cDNA was synthesized using Maxima First Strand cDNA Synthesis Kit (Thermo Scientific). Real-time quantitative PCR was performed using an Applied Biosystems 7300 real-time instrument (Applied Biosystems, Carlsbad, CA, USA). Reverse transcription-PCR product was amplified using the iTaq Universal SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) in a total reaction volume of 20 μl (oligonucleotides for PCR amplification are shown in Table 1 ). Product identity was confirmed by a single pick in the melt curve. Relative expression values were calculated using the 2 − (ΔΔCt) formula. The data are presented as fold change in gene expression normalized to GAPDH and relative to the untreated control. Immunohistochemistry was carried out in formalin-fixed, paraffin-embedded tissue specimens. The antibodies used were rabbit polyclonal anti-MCP-2/CCL8 (orb13564) 1 : 100 by Biorbyt (Berkeley, CA, USA) and rabbit monoclonal (EPR3776) anti-Vimentin (ab92547) 1 : 250 by Abcam (Cambridge, MA, USA); and rabbit monoclonal [SP115] anti-F/480 (ab111101) 1 : 250 by Abcam. Immunostaining was performed by using the Dako EnVision+ System-HRP (DAB, Carpinteria, CA, USA) (K4041), following the manufacturer's instructions. Negative controls included omission of primary antibody. Before evaluation, a weak counterstaining with hematoxylin was performed in all immunostained specimens. Evaluation of samples was performed blindly. For immunoblot analysis and Elisa CCL8 detection, cells and tissues were solubilized with ice-cold RIPA buffer (Thermo Scientific) supplemented with protease inhibitor cocktail (Thermo Scientific). The protein concentration in the lysates was determined by using Bradford assay (Bio-Rad). Equal amounts of total protein were resolved by SDS-PAGE and immunoblotted with rabbit monoclonal (EPR3776) anti-Vimentin and rabbit polyclonal anti-Cytokeratin 18 (ab52948) by Abcam. Plasma, tissues and cell levels of mouse Ccl8 were measured by Mouse CCL8/MCP-2 DuoSet ELISA Development kit (R&D Systems, Minneapolis, MN, USA) according to manufacturer's protocol.
Animal studies
Ccl8KO mice were obtained from KOMP Repository (University of California, Davis, CA, USA) and subsequently bred and maintained at the USC. NCr nude mice were obtained from Taconic (Hudson, NY, USA). Six-to eight-week-old female animals were used for all experiments. Animal studies complied with Institutional guidelines. For tumor reconstitution experiments in C57B6 mice, 1 × 10 5 EO771 cells were resuspended in 0.1 ml of serum-free RPMI and then injected s.c. into C57B6 (n = 19) or Ccl8KO mice (n = 15) (also in C57BL6 background). Animal numbers were determined based on pilot studies and depended on the number of litters for the KO mice. Subsequently, animals were observed daily for tumor development. For antibody treatment, C57B6 mice 6 days after the cell injections were randomly divided into two groups-the first group (n = 10) was treated with mouse anti-CCL8 monoclonal neutralizing antibody (DMABT-H16868; Creative Diagnostics, Shirley, NY, USA; 16 μg per injection) and the second group (n = 10) with normal mouse IgG (sc-2025; Santa Cruz Biotechnology, Santa Cruz, CA, USA; 16 μg per injection). Mice received five daily i.p. injections of anti-CCL8 or IgG. For in vivo metastasis assays in nude mice, 3 × 10 6 MDA231-β-Gal cells were resuspended in 0.1 ml of matrigel and then injected s.c. into nude mice. Six days later, 3 × 10 6 HFFF2 resuspended in 0.1 ml of matrigel were injected next to MDA231-β-Gal matrigel. Three days after fibroblasts inoculation, mice were randomly divided into two groups-the first group (n = 5) was treated with mouse anti-CCL8 monoclonal neutralizing antibody (16 μg per injection) and the second group (n = 4) with normal mouse IgG (6 μg per injection). Mice received three daily i.p. injections of anti-CCL8 or IgG. Mice were killed the next day after the final injection. For CTCs detection, MDA231-β-Gal was injected as described above, and 4 weeks later one group (n = 2) received one i.v. injection of human recombinant CCL8 (Cell Guidance Systems LLC, St Louis, MO, USA; 1.5 μg per injection) and the second group received saline (n = 2). Mice were killed the next day after the final injection. For tumor seeding experiments, 5 × 10 5 MDA231-β-Gal cells resuspended in 0.1 ml of PBS were injected i.v. into nude mice, and 8 h later they were divided into two groups and received four daily i.p. injections of anti-CCL8 (n = 4) or IgG (n = 4). Mice were killed 3 weeks after the final injection and the third thoracic mammary glands were processed for whole-mount analysis.
Histology and staining of tissues
For histological analyses, tumors were fixed in 10% formalin, paraffinembedded and stained with hematoxylin/eosin or Elastica van Gieson (EVG staining kit Millipore (Millipore Corporation, Billerica, MA, USA)) stains for light microscopy. For β-Gal staining of tissues, mammary glands and lungs from nude mice were dissected, cut into~5-mm-thick pieces, fixed in 1.25% glutaraldehyde and subjected to standard β-galactosidase staining. Tissue sections (4-μm-thick) from paraffin-embedded blocks were collected onto poly-L-lysine-coated slides and counterstained with eosin. Images shown were obtained by a Leica ICC50 HD (Buffalo Grove, IL, USA). For whole-mount staining, mammary glands were excised, spread on glass slides and after βgal staining were fixed in Carnoy's fixative overnight at room temperature. Mammary glands were washed in 70% EtOH for 15 min, gradually rehydrated in water and stained in carmine alum overnight at room temperature. Tissues were then gradually dehydrated through serial ethanol baths, cleared in xylene and mounted with Permount mounting medium (Fisher Scientific, Asheville, NC, USA). All staining experiments have been performed at least three times and representative results of one experiment are shown. 
